IP Library › Granted Patent US 12,233,120
Granted Patent B2
US 12,233,120 · App. 18/203,917 · Granted Feb 25, 2025

Proteins and immunizing compositions containing

Inventors: Charles Nelson Carver, III (Willmar, MN); Daryll Emery (Willmar, MN)
Assignee: Vaxxinova US, Inc.
A61K39/102A61K39/39C07K14/285C07K16/1242G01N33/56911A61K2039/552A61K2039/55566G01N2333/285
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,233,120
App. No.
18/203,917
Granted
Feb 25, 2025
Kind
B2
Abstract

The present invention provides isolated proteins isolatable from a Pasteurella spp. such as P. multocida . Also provided by the present invention are compositions that include one or more of the proteins, and methods for making and methods for using the proteins.

Claims (26)

1. A composition comprising a bacterium, the bacterium comprising:

(i) a protein having at least 90% similarity to amino acids 25-968 of SEQ ID NO: 2, a protein having at least 90% similarity to amino acids 27-780 of SEQ ID NO:4, and a protein having at least 90% similarity to amino acids 23-727 of SEQ ID NO:6; or

(ii) a protein having at least 90% similarity to amino acids 25-964 of SEQ ID NO: 8, a protein having at least 90% similarity to amino acids 26-848 of SEQ ID NO:10, a protein having at least 90% similarity to amino acids 27-784 of SEQ ID NO:12, and a protein having at least 90% similarity to amino acids 25-742 of SEQ ID NO:14; and

an adjuvant.

2. The composition of claim 1 , wherein the bacterium is E. coli, Pasteurella, Actinobacillus, Haemophilus , or Lonepinella.

3. The composition of claim 1 , wherein the bacterium further comprises a protein having at least 90% amino acid sequence identity to amino acids 26-805 of SEQ ID NO:44.

4. The composition of claim 2 , wherein the bacterium is engineered to express the protein having at least 90% amino acid sequence identity to amino acids 26-805 of SEQ ID NO:44.

5. The composition of claim 1 , wherein the composition comprises the bacterium comprising (i) the protein having at least 90% similarity to amino acids 25-968 of SEQ ID NO:2, the protein having at least 90% similarity to amino acids 27-780 of SEQ ID NO:4, and the protein having at least 90% similarity to amino acids 23-727 of SEQ ID NO: 6; and the bacterium comprising (ii) the protein having at least 90% similarity to amino acids 25-964 of SEQ ID NO:8, the protein having at least 90% similarity to amino acids 26-848 of SEQ ID NO:10, the protein having at least 90% similarity to amino acids 27-784 of SEQ ID NO: 12, and the protein having at least 90% similarity to amino acids 25-742 of SEQ ID NO: 14.

6. The composition of claim 5 , wherein the bacterium is inactivated.

7. A method comprising: administering to a subject an amount of the composition of claim 1 effective to induce the subject to produce antibody that specifically binds to at least one protein of the composition.

8. A method for treating an infection in a subject, the method comprising: administering an effective amount of the composition of claim 1 to a subject having or at risk of having an infection caused by a P. multocida.

9. A method for treating a symptom in a subject, the method comprising: administering an effective amount of the composition of claim 1 to a subject having or at risk of having an infection caused by a P. multocida.

10. A method for decreasing colonization in a subject, the method comprising: administering an effective amount of the composition of claim 1 to a subject colonized by a P. multocida.

11. The composition of claim 1 , wherein the bacterium is gram negative.

12. The method of claim 1 , wherein the bacterium is engineered to express at least one of the proteins of (i) or at least one of the proteins of (ii).

13. The composition of claim 1 , wherein the composition comprises the bacterium comprising the proteins of (i) and the bacterium comprising the proteins of (ii).

14. A composition comprising two or more bacteria, wherein each bacterium expresses a subset of proteins selected from

a protein having at least 90% similarity to amino acids 25-968 of SEQ ID NO:2,

a protein having at least 90% similarity to amino acids 27-780 of SEQ ID NO:4,

a protein having at least 90% similarity to amino acids 23-727 of SEQ ID NO:6,

a protein having at least 90% similarity to amino acids 25-964 of SEQ ID NO:8,

a protein having at least 90% similarity to amino acids 26-848 of SEQ ID NO:10,

a protein having at least 90% similarity to amino acids 27-784 of SEQ ID NO:12, and

a protein having at least 90% similarity to amino acids 25-742 of SEQ ID NO:14; and

an adjuvant, wherein the two or more bacteria when considered as a whole express all of proteins, and wherein each bacterium of the two or more bacteria express at least two of the proteins.

15. The method of claim 14 , wherein at least one of the bacteria are engineered to express at least one of the proteins.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2024
From: EPITOPIX, LLC
To: VAXXINOVA US, INC.
Reel/Frame 066488/0734 →
Continuity (4)
Continuation 17191913 · Mar 4, 2021
Continuation 16484332
Provisional Application 62457599 · Feb 10, 2017
Related Publication 20230414739A1 · Dec 28, 2023
References Cited (55)
US 5587166A · Donachie · 1996 [cited by applicant]
US 6027736A · Emery · 2000 [cited by applicant]
US 9308247B2 · Narayanan · 2016 [cited by applicant]
US 20090123500A1 · Emery · 2009 [cited by applicant]
EP 0694560A2 · 1996 [cited by applicant]
EP 2431382A1 · 2012 [cited by applicant]
JP 9505085 · 1997 [cited by applicant]
JP 2002541790 · 2002 [cited by applicant]
WO WO9525742 · 1995 [cited by applicant]
WO WO199601620A1 · 1996 [cited by applicant]
WO WO0061724 · 2000 [cited by applicant]
WO WO200061724A2 · 2000 [cited by applicant]
WO WO200137810A2 · 2001 [cited by applicant]
WO WO2007006101A1 · 2007 [cited by applicant]
WO WO2011125015A2 · 2011 [cited by applicant]
WO WO2017011340A2 · 2017 [cited by applicant]
American Type Culture Collection, Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure., Deposited on Behalf of : Willmar Poultry Co., Inc., Serotype A: … [cited by applicant]
Angen et al., “Taxonomic relationships of the [ [cited by applicant]
Arnold et al., “The Swiss-Model workspace: a web-based environment for protein structure homology modelling”, 2006, [cited by applicant]
Bagos et al., “A hidden Markov Model method, capable of predicting and discriminating β-barrel outer membrane proteins”, 2004, [cited by applicant]
Boulianne et al., “Production of functional chimaeric mouse/human antibody”, Dec. 13, 1984, [cited by applicant]
Brüggmann et al., “Production of human antibody repertoires in transgenic mice”, 1997, [cited by applicant]
Carver, “Vaccination with Siderophore Receptors and Porins Protects against Fowl Cholera Challenge by Heterologous Serotypes,” Western Poultry Disease Conference. Sacramento, California, Mar. 20-22, 2017. [cited by applicant]
“Chapter 2.3.9. Fowl Cholera,” in [cited by applicant]
Confer et al, “Intranasal Vaccination of Rabbits with Pasteurella multocida A:3 Outer Membranes that Express Iron-Regulated Proteins” Mar. 2013 [cited by applicant]
Database Geneseq [Online] Feb. 2, 2012 (Feb. 2, 2012), “Drug delivery related pore-forming protein, SEQ 10 2985.” XP055474131, retrieved from EBI accession No. GSP: AZQ49682 Database accession No. AZQ49682. [cited by applicant]
Database JPO Proteins [Online] Sep. 26, 2013 (Sep. 26, 2013), “JP 2013121347-A/107: Anti-Bacterial Vaccine Compositions.”, XP055474134, retrieved from EBI accession No. JPOP:DL676647 Database accession No. DL676647. [cited by applicant]
Daugherty et al., “Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins”, Mar. 1991, Nucleic Ac… [cited by applicant]
Glisson et al, “Cross-Protection Studies with Pasteurella multocida Bacterins Prepared from Bacteria Propagated in Iron-Depleted Medium” Apr. 1993 [cited by applicant]
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse”, May 1986, [cited by applicant]
Ikeda et al, “Antigenically Related Iron-Regulated Outer Membrane Proteins Produced by Different Somatic Serotypes of Pasteurella multocida” Sep. 1988 [cited by applicant]
Keler et al., “Metachromatic Assay for the Quantitative Determinationof Bacterial Endotoxins”, Oct. 1985, [cited by applicant]
Liu et al., “Zinc Sequestration by the Neutrophil Protein Calprotectin Enhances [cited by applicant]
Lomize et al., “OPM database and PPM web server: resources for positioning of proteins in membranes”, Sep. 2011, [cited by applicant]
Lonberg et al., “Antigen-specific human antibodies from mice comprising four distinct genetic modifications”, Apr. 1994, [cited by applicant]
Lobuglio et al., “Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response”, Jun. 1989, [cited by applicant]
Mikayama et al., “Molecular Cloning and Functional Expression of a cDNA encoding Glycosylation-Inhibiting Factor”, [cited by applicant]
Mietinen, “Proportion of Disease Caused or Prevented by a Given Exposure, Trait or intervention”, 1974, [cited by applicant]
Morrison et al., “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains”, 1984, [cited by applicant]
Petersen et al., “SignalP 4.0: discriminating signal peptides from transmembrane regions”, Oct. 2011, [cited by applicant]
Patent Application No. PCT/US2018/017682, filed Feb. 9, 2018; [International Search Report / Written Opinion] issued Aug. 16, 2018; 21pages. [cited by applicant]
Patent Application No. PCT/US2018/017682, filed Feb. 9, 2018; [International Preliminary Report on Patentability] issued Aug. 22, 2019; 14 pages. [cited by applicant]
Queen et al., “A humanized antibody that binds to the interleukin 2 receptor”, Dec. 1989, [cited by applicant]
Rice et al., “EMBOSS: The European Molecular Biology Open Software Suite” Jun. 2000, [cited by applicant]
Riechmann et al., “Reshaping human antibodies for therapy” Mar. 1988, [cited by applicant]
Roier et al, “Immunogenicity of Pasteurella multocida and Mannheimia haemolytica outer membrane vesicles” Jul. 2013 [cited by applicant]
Rudinger et al., “Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence,” Peptide Hormones, Biol. Council, pp. 507, Jun. 1976. [cited by applicant]
Stork et al., “An Outer Membrane Receptor of [cited by applicant]
“Supplemental Assay Method for Potency Testing of Fowl Cholera ( [cited by applicant]
Tatusova et al., “BLAST 2 Sequences, a new tool for comparing protein and nucleotide sequences”, 1999, [cited by applicant]
Taylor et al., “A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins” 1992, [cited by applicant]
Wilson et al., “Comparison of DNA Fingerprinting and serotyping for Identification of Avian [cited by applicant]
Office Action issued in Japan for Application No. 2019-543050 dated Jan. 19, 2022 (15 pages). English translation included. [cited by applicant]
Office Action issued in Europe for Application No. 18708005.6-1112 dated Jul. 30, 2020 (8 pages). [cited by applicant]
Office Action issued in Europe for Application No. 18708005.6-1112 dated Mar. 25, 2021 (4 pages). [cited by applicant]